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Abstract
Background: Most data on prostate-specific antigen (PSA) testing come from urologic cohorts
comprised of volunteers for screening programs. We evaluated the diagnostic accuracy of PSA
testing for detecting prostate cancer in community practice.
Methods: PSA testing results were compared with a reference standard of prostate biopsy.
Subjects were 2,620 men 40 years and older undergoing (PSA) testing and biopsy from 1/1/95
through 12/31/98 in the Albuquerque, New Mexico metropolitan area. Diagnostic measures
included the area under the receiver-operating characteristic curve, sensitivity, specificity, and
likelihood ratios.
Results: Cancer was detected in 930 subjects (35%). The area under the ROC curve was 0.67 and
the PSA cutpoint of 4 ng/ml had a sensitivity of 86% and a specificity of 33%. The likelihood ratio
for a positive test (LR+) was 1.28 and 0.42 for a negative test (LR-). PSA testing was most sensitive
(90%) but least specific (27%) in older men. Age-specific reference ranges improved specificity in
older men (49%) but decreased sensitivity (70%), with an LR+ of 1.38. Lowering the PSA cutpoint
to 2 ng/ml resulted in a sensitivity of 95%, a specificity of 20%, and an LR+ of 1.19.
Conclusions:  PSA testing had fair discriminating power for detecting prostate cancer in
community practice. The PSA cutpoint of 4 ng/ml was sensitive but relatively non-specific and
associated likelihood ratios only moderately revised probabilities for cancer. Using age-specific
reference ranges and a PSA cutpoint below 4 ng/ml improved test specificity and sensitivity,
respectively, but did not improve the overall accuracy of PSA testing.
Background
Prostate cancer is the most frequently diagnosed visceral
cancer in the United States and the second leading cause
of cancer death in men [1]. Unfortunately, there are no
proven primary prevention strategies for prostate cancer
and no curative treatments for distant-stage cancers [2,3].
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Consequently, cancer control efforts have focused on de-
tecting early-stage prostate cancer with screening tests and
then aggressively treating the cancer with surgery or radia-
tion. The most effective screening test is the prostate-spe-
cific antigen (PSA) assay, which in combination with
digital rectal examination (DRE) substantially enhances
the cancer detection rate [4]. The American Cancer Society
and the American Urologic Association recommend an-
nual cancer screening with PSA testing and digital rectal
examination for men with life expectancies greater than
10 years [5,6]. However, the United States Preventive Serv-
ices Task Force and the American College of Physicians
have not endorsed routine screening because there is no
conclusive evidence that screening and treatment reduce
morbidity and mortality from prostate cancer [7,8]. An-
other concern about prostate cancer screening is uncer-
tainty about the diagnostic performance of PSA. The
available data on PSA testing generally come from urolog-
ic case series comprised of volunteers responding to ad-
vertisements for screening [9–11]. However, PSA
screening recommendations encompass the entire popu-
lation of men at risk for prostate cancer and results from
the urologic literature may not be fully generalizable. We
have not found any large community-based studies evalu-
ating the accuracy of PSA testing.
In this report we link PSA testing and prostate biopsy data
from the Albuquerque, New Mexico metropolitan area
with population-based cancer registry data collected by
the New Mexico Tumor Registry (NMTR), a participant in
the National Cancer Institute's Surveillance, Epidemiolo-
gy, and End Results (SEER) Program. The objective of our
study was to evaluate the diagnostic accuracy of PSA test-
ing for detecting prostate cancer in community practice.
Methods
Data collection
We collected computerized data from four major clinical
laboratories in Albuquerque, New Mexico on PSA testing
occurring from January 1, 1995 through December 31,
1997. These laboratories provided testing services for uni-
versity, Veterans Affairs, Health Maintenance Organiza-
tions, and private plan patients within the four-county
Albuquerque metropolitan area. Data included test date,
PSA level, and patient demographics, including birth date,
age at testing, and personal identifiers. Additionally, we
used the GUESS program, a validated algorithm devel-
oped at the University of New Mexico, to identify ethnic
background based on surname [12]. We evaluated only
men age 40 years and older at the time of initial testing.
The PSA testing data were matched with the NMTR data-
base to exclude PSA tests ordered for cancer surveillance
and to identify incident cases of prostate cancer diagnosed
between January 1, 1995 and December 31, 1998. The
NMTR database provided information on cancer stage, us-
ing the SEER categories of local, regional, and distant.
Trained medical record abstractors from the NMTR also
collected data from area laboratories on all benign pros-
tate biopsies during the same time period. The human
subjects committees of the participating hospitals and lab-
oratories approved the study protocol.
Data analysis
We evaluated the diagnostic accuracy of PSA testing using
subjects in the PSA-tested cohort who had a confirmed di-
agnosis of incident prostate cancer and using subjects who
underwent at least one prostate biopsy and were not diag-
nosed with prostate cancer during the study period. For a
subject to be included in this analysis, we required that a
PSA result be obtained within 12 months before a cancer
diagnosis or a negative biopsy result. If a subject had mul-
tiple negative biopsies, we analyzed the first biopsy that
could be linked to a PSA test within the preceding 12
months. If subjects had multiple PSA tests within 12
months preceding a negative biopsy or cancer diagnosis,
we analyzed the first PSA test. Clinical characteristics of
cases and controls were compared with chi-square tests for
categorical variables and either t-tests or the Mann-Whit-
ney U test for continuous variables. Linear regression
analyses were used to test for linear trends. Statistical tests
were performed with the software program Statistica [13].
We constructed receiver operating characteristic (ROC)
curves by plotting sensitivity against 1 – specificity. We es-
timated the discriminating power of PSA testing by deter-
mining the area under the ROC curve using the method of
Hanley and McNeil [14]. ROC curves were constructed for
the entire cohort, for 10-year age ranges, and for non-His-
panic whites and Hispanics. We also constructed an ROC
curve using only cases with localized cancers, the target of
PSA screening.
PSA accuracy was evaluated according to standard epide-
miologic definitions for specificity, sensitivity, likelihood
ratios, and predictive values [15]. Briefly, we defined sen-
sitivity as the proportion of cancer cases with an elevated
PSA; specificity is the proportion of non-cancer controls
with a normal PSA. The positive predictive value of a test
is the proportion of subjects with an abnormal test result
who have the target disorder. The negative predictive val-
ue is the proportion of subjects with a normal test result
who do not have the target disorder. A likelihood ratio
compares the proportion of people with and without the
target disorder within a stratum of diagnostic test results.
Likelihood ratios provide a magnitude of probability revi-
sion using a version of Bayes' theorem:
Post-test odds for the target disorder = Pre-test odds for
the target disorder × Likelihood ratio for diagnostic test re-
sultsBMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/19
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The diagnostic accuracy of PSA testing was further evalu-
ated by examining different PSA cutpoints, by stratifying
analyses into five age ranges (40 to 49, 50 to 59, 60 to 69,
70 to 79, and ≥ 80 years), and by using age-specific PSA
reference ranges [16]. We also looked at stratum-specific
likelihood ratios and predictive values for the following
PSA strata: < 2 ng/ml, ≥ 2 – 4 ng/ml, > 4 – 10 ng/ml, > 10
– 20 ng/ml, and > 20 ng/ml. An Excel spreadsheet devel-
oped by Peirce and Cornell was used to compute likeli-
hood ratios and 95% confidence intervals for different
PSA cutpoints and test-result strata [17].
Results
Subject characteristics
We obtained data on 41,261 men without a previous di-
agnosis of prostate cancer who underwent PSA testing at
Albuquerque, New Mexico laboratories between January
1, 1995 and December 31, 1997. By the end of 1998,
2,620 (6.3%) of the testing cohort had undergone a pros-
tate biopsy within 12 months following an initial PSA test
and 930 (2.3%) of these men were diagnosed with pros-
tate cancer. The median age at testing was 61 years (25th
percentile 52, 75th percentile 69); 63.4% of the men were
non-Hispanic white and 28.3% were Hispanic. The medi-
an PSA value for cancer patients (7.8 ng/ml, 25th percen-
tile 4.9, 75th percentile 14.2) was significantly higher than
the median value for patients without cancer (5.4 ng/ml,
25th percentile 2.7 ng/ml, 75th percentile 8.1), P < 0.0001.
Cancer patients were also significantly older, with a medi-
an age of 68 years (25th percentile 63, 75th percentile 67)
vs. 66 years (25th percentile 60, 75th percentile 71), P <
0.0001.
Diagnostic accuracy
The discriminating power of PSA testing for detecting
prostate cancer, as estimated by the area under the ROC
curve (Figure. 1), was 0.67 (SE 0.02). When we analyzed
the ROC curve just using the 796 cases with localized can-
cers, we found a similar area of 0.64 (SE 0.01). The dis-
criminating power remained relatively constant across age
ranges, with areas of 0.70, 0.68, 0.63, 0.65, and 0.69 for
men in their 40s, 50s, 60s, 70s, and 80s, respectively. The
area under the ROC curve was 0.66 for non-Hispanic
whites compared to 0.69 for Hispanics.
Estimates for sensitivity, specificity, and predictive values
for different PSA cutpoints, stratified by age range, are re-
ported in Tables 1 and 2. Data are presented for men in
their 50s and 60s in Table 1, and for men in their 70s and
all age groups combined (including men in their 40s and
men 80 years and older) in Table 2. For the standard PSA
cutpoint of 4 ng/ml, test sensitivity was 86% and specifi-
city was 33%. With this cutpoint, the likelihood ratio for
a positive test was 1.28 (95% CI 1.23 to 1.34) and 0.42
(95% CI 0.36 to 0.50) for a negative test.
Raising the cutpoint to 10 ng/ml decreased the sensitivity
to 38% while specificity increased to 84%. The associated
likelihood ratio for a positive test was 2.38 (95% CI 2.08
to 2.72) and 0.74 (95% CI 0.70 to 0.78) for a negative test.
Lowering the cutpoint to 2 ng/ml increased the sensitivity
to 95% but dropped specificity to 20%. At this cutpoint
the likelihood ratio for a positive test was 1.19 (95% CI
1.15 to 1.22) and 0.25 (95% CI 0.19 to 0.34) for a nega-
tive test. The predictive value for PSA was significantly cor-
related with PSA cutpoint level, P = 0.01 for linear trend,
ranging from 39% for PSA levels ≥ 2 ng/ml to 78% for PSA
levels ≥ 20 ng/ml.
Stratum-specific likelihood ratios and predictive values
are presented in Table 3. We found that the likelihood ra-
tio for PSA levels between 4 and 10 ng/ml was statistically
equivalent to 1, indicating that no significant probability
revision occurred with testing. PSA values less than 2 ng/
ml or greater than 20 ng/ml produced the largest proba-
bility revisions for detecting prostate cancer.
Table 4 shows the diagnostic accuracy for PSA levels ≥ 4
ng/ml stratified by age. The sensitivity of PSA significantly
increased with age, going from 75% for men in their 40s
to 90% in men 70 years and older, P = 0.03 for linear
trend. However, specificity significantly decreased from
56% in the younger men to 27% in older men, P = 0.03
Figure 1
Receiver-operating characteristic curve for PSA testing in
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for linear trend. With age-specific references ranges (Table
5) we found that, compared to the traditional cutpoint of
4 ng/ml, sensitivity was higher in the younger age ranges
and specificity was higher in the older age ranges. Overall,
however, the magnitudes of the likelihood ratios with age-
specific reference ranges were similar to those found with
the 4 ng/ml cutpoint, except for higher likelihood ratios
following negative tests in men 70 years and older. The
sensitivity and specificity of PSA, using either a cutpoint of
4 ng/ml or age-specific reference ranges, did not differ sig-
nificantly between non-Hispanic white and Hispanic men
(data not shown).
Table 1: Diagnostic accuracy of PSA: ages 50 – 59, 60 – 69
PSA cutpoint 
(ng/mL)
Ages 50 – 59 (131 cases, 335 controls) Ages 60 – 69 (382 cases, 771 controls)
Sens Spec PPV NPV Sens Spec PPV NPV
1 100 16 32 10 97 8 35 87
2 9 42 73 49 29 51 93 78 8
3 8 93 53 58 98 92 43 78 2
4 8 40 34 84 84 32 38 80
5 6 35 43 57 97 04 23 87 4
6 4 86 93 87 75 85 74 07 3
7 4 37 94 47 85 06 84 37 3
8 3 78 54 97 74 37 54 67 3
9 3 18 95 37 73 68 14 97 2
10 25 92 55 76 31 85 51 71
15 15 98 70 75 18 95 63 70
20 11 98 88 74 13 97 76 70
Abbreviations: PSA = prostate-specific antigen. Sens = sensitivity. Spec = specificity. PPV = positive predictive value. NPV = negative predictive value
Table 2: Diagnostic accuracy of PSA: ages 70 – 79, all subjects
PSA cutpoint 
(ng/mL)
Ages 70 – 79 (345 cases, 480 controls) All subjects* (930 cases, 1690 controls)
Sens Spec PPV NPV Sens Spec PPV NPV
19 9 5 4 3 8 8 9 8 9 3 7 9 1
2 9 71 34 58 49 52 03 98 8
3 9 32 14 68 19 12 64 08 4
4 8 92 74 77 88 63 34 18 1
5 8 33 64 87 57 54 44 27 6
6 7 24 64 97 06 35 74 57 4
7 6 55 45 16 85 66 64 87 3
8 5 56 45 26 74 97 45 17 2
9 4 87 15 46 54 28 05 37 1
10 44 76 57 65 38 84 56 71
15 27 89 65 63 23 93 67 69
20 18 95 74 62 17 97 78 68
*Including subjects 40 – 49 years, 80 years and older. Abbreviations: PSA = prostate-specific antigen. Sens = sensitivity. Spec = specificity. PPV = 
positive predictive value. NPV = negative predictive valueBMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/19
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Discussion
We evaluated the diagnostic performance of PSA testing
using a community-based analysis of men who under-
went prostate biopsy within 12 months of PSA testing.
Data were analyzed for 930 prostate cancer cases and
1690 controls ages 40 years and older. The area under the
ROC curve was 0.67, indicating fair discriminating power
for detecting prostate cancer. PSA testing performed
equally well in detecting localized cancers and in detect-
ing cancers across all age ranges and in non-Hispanic
white and Hispanic men. The standard cutpoint of 4 ng/
ml had a sensitivity of 86% and a specificity of 33% and
was most sensitive – but least specific – for older men. The
4 ng/ml cutpoint was associated with a likelihood ratio
for a positive test of 1.28 and 0.42 for a negative test, rep-
resenting only moderate probability revisions [18]. PSA
values < 2 ng/ml or greater than 20 ng/ml were associated
with large probability revisions. Likelihood ratios did not
change substantially when we used age-specific reference
ranges, though test sensitivity decreased with increasing
age while specificity increased. Lowering the PSA cutpoint
to 2 ng/ml raised the sensitivity to 97% but led to an 80%
false positive rate.
Most previous reports from the urologic literature provid-
ed similar estimates for the discriminating power of the
PSA test. Areas under the ROC curve have been reported
to range from 0.65 to 0.77 in case series comprised of pa-
tients enrolled in screening trials [4,19–21] or followed in
urologic practice [22]. Among urologic studies, we found
only Labrie and colleagues reporting a substantially high-
er area under the ROC curve: 0.88 (SE 0.03) [23]. Howev-
er, biopsies were performed only when digital rectal or
transrectal ultrasound examinations were abnormal,
which would inflate the apparent sensitivity of an elevated
PSA level. Gann and colleagues reported an area under the
ROC curve of 0.83 in a nested case-control study of Physi-
cians Health Study participants with 10 years of follow-up
[24]. Stored serum from cases clinically diagnosed with
prostate cancer and age-matched controls were assayed for
PSA. However, the specificity of PSA was probably overes-
timated because asymptomatic men were unlikely to be
biopsied.
We identified only three population-based studies evalu-
ating PSA testing performance [23,25,26]. The two uro-
logic studies [23,25] randomly selected men from either
electoral rolls or census records and invited them to have
prostate examinations. However, neither study used PSA
levels as a criterion for biopsy thus confounding the re-
ported predictive values with results from digital rectal ex-
aminations and transrectal ultrasonography. Jacobsen
and colleagues conducted a retrospective, case-control
study analyzing 177 prostate cancer cases diagnosed in
Olmsted County, Minnesota in the early 1990s [26]. PSA
was highly discriminating with an area under the ROC
curve of 0.94 (SE, 0.01) for all patients. Age-stratified
analyses showed that the discriminating power remained
high across all age groups, even for men in their 70s. Test
sensitivity was approximately 85% for all age groups,
though specificity decreased from 98% among men in
their 50s to 81% among men in their 70s.
Methodologic differences in study design may explain the
disparities in the results between the New Mexico and
Minnesota cohorts. Controls in Olmsted County were
drawn from a longitudinal Mayo Clinic study on the nat-
ural history of lower urinary tract symptoms. Men with in-
itial PSA elevations > 4 ng/ml or an abnormal DRE were
biopsied and cancer cases were excluded. However, men
with normal PSA and DRE results did not undergo biopsy,
thus potentially inflating estimates for specificity. Sensi-
tivity may have been higher if urologists at the Mayo Clin-
ic had a lower false negative biopsy rate than did New
Mexico urologists.
Our estimates for the sensitivity (86%), specificity (33%),
and positive predictive value (41%) for PSA levels ≥ 4 ng/
ml were similar to previously reported values. In the uro-
logic literature, sensitivities ranged from 67% to 90%, spe-
cificities ranged from 28% to 59%, and positive predictive
values ranged from 30% to 43% [9–11,19,20,27,28].
Table 3: Stratum specific likelihood ratios for PSA test-result strata
PSA range (ng/mL) Number of subjects SSLR (95% CI)
< 2 378 0.25 (0.19, 0.34)
≥ 2 – 4 313 0.69 (0.55, 0.87)
> 4 – 10 1302 0.96 (0.88, 1.04)
> 10 – 20 421 1.48 (1.24, 1.76)
> 20 206 6.34 (4.62, 8.70)
Abbreviations: PSA = prostate-specific antigen. SSLR = stratum-specific likelihood ratio. CI = confidence interval.BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/19
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However, almost all of the published studies, including
our own, are flawed by potential work-up bias because
men with elevated PSA levels were significantly more like-
ly to be biopsied. In our cohort, men with a PSA level ≥ 4
ng/ml had a 15-fold increased rate of biopsy compared to
men with normal values.
Accurately estimating the true and false negative rates for
PSA requires that men with normal PSA values undergo
biopsy, but we found only one small urologic series where
all PSA-tested subjects were subsequently biopsied. Val-
lencian and colleagues biopsied 100 consecutive men
with normal or non-suspicious digital rectal examinations
and detected only 14 cancers, none with PSA levels below
10 ng/ml [29]. The Gann study provided the least biased
estimate of sensitivity and specificity, but even these re-
sults were limited because asymptomatic cancers would
not have been detected [24]. Additionally, serum was
stored for about 10 years and PSA is not completely stable
[30,31].
Modifications of the PSA level have been proposed to im-
prove the discriminating power of the test. Oesterling and
colleagues developed age-specific PSA reference ranges
that lowered the cutpoint in younger men, to increase sen-
sitivity, and raised the cutpoint in older men in order to
increase specificity [16]. We found that using age-specific
reference ranges did not substantially change likelihood
ratios for prostate cancer, though we confirmed that sen-
sitivity would increase in younger men and specificity
would increase in older men.
The age-specific reference ranges have been further modi-
fied for racial differences in PSA and cancer risk [32]. Be-
cause African-Americans have an increased incidence of
prostate cancer and higher PSA levels at diagnosis, the age-
specific reference ranges have been adjusted to maintain a
high sensitivity [32–34]. Our study cohort had too few Af-
rican-Americans for a subgroup analysis, but we were able
to compare non-Hispanic white with Hispanic men. We
found that PSA testing discriminated equally well for His-
panics and non-Hispanic whites and that PSA cutpoints
do not need to be adjusted for Hispanics. We are unaware
of any other studies comparing the performance of PSA
testing between non-Hispanic white and Hispanic men,
though Abdalla and colleagues have reported similar PSA
levels in non-Hispanic white and Hispanic men with and
without prostate cancer [35,36].
Some investigators are now recommending that lower
PSA cutpoints should be used as an indication for prostate
biopsy [37–39]. Catalona and colleagues detected cancer
in 22% of men biopsied with PSA levels between 2.6 to 4
ng/ml [37] and Lodding and colleagues detected cancers
Table 4: Diagnostic accuracy of PSA levels ≥ 4 ng/ml stratified by age
Age Sensitivity (%) Specificity (%) LR + (95% CI) LR – (95% CI)
40 – 49 75 55 1.68 (1.17, 2.40) 0.45 (0.21, 0.95)
50 – 59 80 40 1.34 (1.19, 1.52) 0.49 (0.34, 0.71)
60 – 69 84 32 1.24 (1.16, 1.32) 0.50 (0.39, 0.64)
≥ 70 90 27 1.23 (1.16, 1.32) 0.37 (0.27, 0.51)
Abbreviations: PSA = prostate-specific antigen. LR+ = likelihood ratio for a positive test. LR- = likelihood ratio for a negative test. CI = confidence 
interval.
Table 5: Diagnostic accuracy of age-specific PSA levels
Age PSA cutoff (ng/mL) Sensitivity (%) Specificity (%) LR + (95% CI) LR – (95% CI)
40 – 49 2.5 85 42 1.47 (1.11, 1.93) 0.35 (0.13, 0.96)
50 – 59 3.5 86 38 1.38 (1.25, 1.54) 0.36 (0.24, 0.56)
60 – 69 4.5 78 36 1.22 (1.14, 1.32) 0.60 (0.49, 0.74)
≥ 70 6.5 70 49 1.38 (1.24, 1.53) 0.61 (0.52, 0.73)
Abbreviations: PSA = prostate-specific antigen. LR+ = likelihood ratio for a positive test. LR- = likelihood ratio for a negative test. CI = confidence 
interval.BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/19
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in 13% of men with PSA values between 3 to 4 ng/ml [39].
We found that lowering the cutpoint to 2 ng/ml, while
greatly increasing sensitivity, led to an 80% false positive
rate.
Aside from work-up bias, there were some other impor-
tant limitations in our study. We do not know the indica-
tions for testing or results from digital rectal
examinations. The positive predictive value of 41% that
we found for a PSA cutpoint of 4 ng/ml was at the high
end of values reported in screening studies and cancer was
detected in 24% of men in our cohort with normal PSA
levels. These findings suggest that our estimates for sensi-
tivity and specificity may be less applicable to a true
screening population. However, we believe that our re-
sults more accurately reflect community testing practices
than the data reported by urologic series of volunteer sub-
jects. Finally, our study cohort was largely comprised of
non-Hispanic white and Hispanic men. Data suggest that
the PSA assay may perform differently in African-Ameri-
cans and our results may not be generalizable to other
populations [32].
Conclusions
Our community-based study showed that PSA testing had
fair discriminating power for detecting prostate cancer
with an area under the ROC curve of 0.67. PSA testing had
similar discriminating power for detecting localized can-
cers, and it performed equally well across age ranges and
in different ethnic groups. The PSA cutpoint of 4 ng/ml
was sensitive but relatively non-specific and likelihood ra-
tios for this cutpoint demonstrated only moderate proba-
bility revisions. Although age-specific reference ranges
improved sensitivity in younger men and specificity in
older men, they did not substantially change likelihood
ratios for cancer. Lowering the PSA cutpoint below 4 ng/
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